trending Market Intelligence /marketintelligence/en/news-insights/trending/hTpa11FBCU91BTKZUjgRww2 content esgSubNav
In This List

Cellectar Biosciences closes $7.8M registered direct offering

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Cellectar Biosciences closes $7.8M registered direct offering

Cellectar Biosciences Inc. closed a registered direct offering of 1,954,388 common shares and 41.0412949 preferred shares.

The preferred stock was offered at $100,000 per share and is immediately convertible into about 53,369 shares for a total of 2,190,330 shares upon conversion at a price of $1.87375 per share.

The company received gross proceeds of about $7.8 million.

Cellectar Biosciences also offered the purchasers series D warrants to buy an aggregate of 3,108,538 common shares as part of a concurrent private placement.

The warrants have an exercise price of $1.78, will be immediately exercisable and will expire in 7 years.

Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent in connection with the offering.